<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283932</url>
  </required_header>
  <id_info>
    <org_study_id>PAN/23/88/04-05</org_study_id>
    <nct_id>NCT01283932</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition</brief_title>
  <official_title>A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single dose bioavailability of pantoprazole sodium 40 mg delayed release
      tablets (Dr. Reddy's Laboratories Ltd, India) with Protonix® 40 mg delayed release tablets
      (Wyeth Laboratories, USA) in 52 (+ 6 standby) healthy, adult, human subjects under fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Open label, balanced, randomized two-treatment, two-period,two-sequence, crossover
      bioequivalence study with at least 07 days washout period between each drug administration
      under fed conditions.52 (+6 standby) healthy, adult, human subjects were enrolled. A single
      oral dose of 40 mg of pantoprazole delayed release tablet will be administered along with 240
      mL of drinking water within 30 minutes after serving a high fat breakfast.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax and AUC parameters</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>FED</condition>
  <arm_group>
    <arm_group_label>Pantoprazole Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protonix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protonix 40 mg DR Tablets of Wyeth Laboratories</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole Sodium</intervention_name>
    <description>Pantoprazole Sodium DR Tablets 40 mg</description>
    <arm_group_label>Pantoprazole Sodium</arm_group_label>
    <arm_group_label>Protonix</arm_group_label>
    <other_name>Protonix DR Tablets 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects will provide written informed consent.

          2. Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing
             at least 50 kg.

          3. Subjects must be within ±10% of ideal body weight in relation to height according to
             Life Insurance Corporation of India height-weight chart for non-medical cases.

          4. Subjects must be of normal health as determined by medical history and physical
             examination performed within 15 days prior to the commencement of the study.

          5. Have normal EcG, X-ray and vital signs.

          6. Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent.

          7. If subject is a female volunteer and

               1. Is of child bearing potential practicing an acceptable method of birth control
                  for the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

               2. is postmenopausal for at least 1 year.

               3. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria:

          1. Subjects incapable of understanding the informed consent.

          2. Subjects with BP≤90/60 or BP≥140/90

          3. History of hypersensitivity or idiosyncratic reaction to pantoprazole or other proton
             pump inhibitors.

          4. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          5. Regular smoker who smokes more than ten cigarettes daily and has difficulty in
             abstaining from smoking for the duration of each study period.

          6. Subjects who has taken over the counter or prescribed medications, including any
             enzyme modifying drugs or any systemic medication within the past 30 days prior to
             start of clinical period.

          7. History of any psychiatric illness, which may impair the ability to provide written,
             informed consent.

          8. Subjects who have a history of alcohol or substance abuse within the last 5 years.

          9. Subjects with clinically significant abnormal values of laboratory parameters.

         10. Subjects who have participated in any other clinical investigation using experimental
             drug or had bled more than 350 mL in the past 3 months.

         11. Subjects with positive urine screen for drugs of abuse.

         12. Any subject in whom pantoprazole is contraindicated for medical reasons.

         13. Female volunteers demonstrating a positive pregnancy screen.

         14. Female volunteers who are currently breast-feeding.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mangesh Kulkarni, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>VimtaLabsLtd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VimtaLabsLtd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhrapradesh</state>
        <zip>500 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vice President-Research and Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

